11 Mai 2021 | News
In the past few months, and due to the recently initiated Phase I/IIa Clinical Trial of the bacteriophage cocktail TP-102, which has been entirely developed in the company for the treatment of diabetic foot ulcers infected by Pseudomonas aeruginosa, Acinetobacter...
27 Abr 2021 | News
Technophage has been recently featured in the TV show ‘Exame Informática’. In this piece, you can quickly learn a bit more about our bacteriophage cocktail TP-102, also gaining an opportunity to a virtual tour of our GMP production unit. TechnoPhage...
6 Jan 2021 | News
Technophage has been awarded by IAPMEI (Agency for Competitiveness and Innovation) with the distinction of ‘PME líder’. This certification acknowledges the financial performance of Portuguese Small and Medium Enterprises (SME) and refers to the year 2020....
17 Ago 2020 | News
In 2019, Technophage was among the top 100 companies with the highest R&D investment in Portugal. According to the provisional results of the IPCTN19, the 100 companies or groups with more intramural investment in R&D are responsible for 47% of the total...
4 Abr 2020 | News
Since the 1st January 2020, Technophage is a resident company of Johnson & Johnson Innovation, JLABS, a premier life science incubator program. JLABS is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the...
